GlassScriptPhysician profile
Tarsem C Garg
NPI 1639269434
$1,139.04
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $59.30 · 2021: $303 · 2022: $332.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $174.82 | 2020-2022 | |
| Genzyme Corporation | $169.49 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.46 | 2022 | |
| Abbvie INC. | $92.42 | 2021 | |
| Smith+Nephew, INC. | $87.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.74 | 2021 | |
| Daiichi Sankyo INC. | $82.96 | 2021 | |
| Akebia Therapeutics INC | $75.25 | 2019 | |
| Lilly USA, LLC | $74.12 | 2019 | |
| Amgen INC. | $61.06 | 2019 | |
| Organogenesis INC. | $46.30 | 2019 | |
| Alnylam Pharmaceuticals INC. | $40.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.68 | 2019 | |
| Boston Scientific Corporation | $13.03 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarsem Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.